Display Settings:

Format

Send to:

Choose Destination
Nat Rev Cancer. 2007 Nov;7(11):880-7.

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.

Author information

  • 1Fondazione IRCCS Istituto Nazionale Tumori Experimental Oncology, Via G. Venezian 1, Milan, 20133 Italy. mario.colombo@istitutotumori.mi.it

Abstract

Tumour-induced expansion of regulatory T (T(Reg)) cells is an obstacle to successful cancer immunotherapy. The potential benefit of T(Reg)-cell depletion through the interleukin-2 receptor is lost by the concurrent elimination of activated effector lymphocytes and possibly by the de novo induction of T(Reg)-cell replenishment. In theory, the functional inactivation of T(Reg) cells will maintain them at high numbers in tumours and avoid their replenishment from the peripheral lymphocyte pool, which has the capacity to further suppress the effector lymphocyte anti-tumour response.

PMID:
17957190
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk